IP Library Granted Patent US 11,052,097
Granted Patent B2
US 11,052,097 · App. 14/130,883 · Granted Jul 6, 2021

Oligosaccharides composition for preventing or reducing the risk of metabolic syndrome

Inventors: Georgios Tzortzis (Berkshire, GB); Jelena Vulevic (Berkshire, GB)
A61K31/702A61K31/7016A61P31/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,052,097
App. No.
14/130,883
Granted
Jul 6, 2021
Kind
B2
Abstract

The present invention relates to the use of a galactooligosaccharide composition for preventing or reducing the risk of developing metabolic syndrome.

Claims (6)

1. A method for lowering levels of total cholesterol, triglycerides, and/or non-esterified fatty acids in a human, the method comprising administering to a human with elevated levels of total cholesterol, triglycerides, and/or non-esterified fatty acids an effective amount of a galactooligosaccharide composition comprising a mixture of galactooligosaccharides comprising disaccharides Gal (β1-3)-Glc; Gal (β1-3)-Gal; Gal (β1-6)-Gal; Gal (α1-6)-Gal; trisaccharides Gal (β1-6)-Gal (β1-4)-Glc; Gal (β1-3)-Gal (β1-4)-Glc; tetrasaccharide Gal (β1-6)-Gal (β1-6)-Gal (β1-4)-Glc and pentasacharide Gal (β1-6)-Gal (β1-6)-Gal (β1-6)-Gal (β1-4)-Glc;

wherein the galactooligosaccharide composition is administered without a probiotic strain.

2. The method according to claim 1 wherein the composition is in the form of a freeze-dried powder, a syrup, or a pastille.

3. The method according to claim 1 wherein the galactooligosaccharide composition is administered orally on a daily basis as a single dose or two separate doses.

4. The method according to claim 2 wherein the composition is in the form of a freeze-dried powder composition, comprising from 1.35 g to 9.6 g of galactooligosaccharides in 2.75 g to 20 g of the freeze-dried powder composition.

5. The method according to claim 2 wherein the composition is in the form of a syrup composition, comprising from 1.35 g to 9.6 g of galactooligosaccharides in 3.55 g to 25.29 g of the syrup composition.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 9, 2024
From: CLASADO RESEARCH SERVICES LIMITED
To: CLASADO LIMITED
Reel/Frame 067048/0113 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 27, 2021
From: CLASADO INC.
To: CLASADO RESEARCH SERVICES LIMITED
Reel/Frame 055045/0947 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 16, 2014
From: TZORTZIS, GEORGIOS; VULEVIC, JELENA
To: CLASADO INC.
Reel/Frame 031990/0241 →
Priority Claims (1)
GB 1111452 · Jul 5, 2011 · national
Continuity (1)
Related Publication 20140142061A1 · May 22, 2014